A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis

Therapeutic Advances in Musculoskeletal Disease

Volumn 5, Issue 3, 2013, Pages 127-139

  Cianferotti, Luisella ^a   D’asta, Federica ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

anabolic; antiresorptive; bone formation; bone mineral density; bone resorption; mineralization; safety; tolerability

Indexed keywords

ALENDRONIC ACID; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN; CALCITONIN; CALCIUM; CALCIUM SENSING RECEPTOR; GLUCOCORTICOID; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; SULFONAMIDE; TRANSCRIPTION FACTOR RUNX2; VITAMIN D;

ADIPOGENESIS; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE MATRIX; BONE MINERALIZATION; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CELL PROLIFERATION; CLAVICLE FRACTURE; COST BENEFIT ANALYSIS; DERMATITIS; DIARRHEA; DRESS SYNDROME; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMUR NECK FRACTURE; HEADACHE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MORBIDITY; MORPHOMETRICS; MORTALITY; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PELVIS FRACTURE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RASH; RIB FRACTURE; RISK FACTOR; RISK REDUCTION; SECONDARY OSTEOPOROSIS; SIGNAL TRANSDUCTION; SPINE FRACTURE; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WRIST FRACTURE;

EID: 84887446742     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X13483187     Document Type: Article

References (73)

1. Ammann P. Badoud I. Barraud S. Dayer R. Rizzoli R. (2007) Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 22: 1419–1425.
2. Ammann P. Shen V. Robin B. Mauras Y. Bonjour J. Rizzoli R. (2004) Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 19: 2012–2020.
3. Arlot M. Jiang Y. Genant H. Zhao J. Burt-Pichat B. Roux J. et al (2008) Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 23: 215–222.
4. Atkins G. Welldon K. Halbout P. Findlay D. (2009) Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20: 653–664.
5. Bain S. Jerome C. Shen V. Dupin-Roger I. Ammann P. (2009) Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 20: 1417–1428.
6. Barbara A. Delannoy P. Denis B. Marie P. (2004) Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells. Metabolism 53: 532–537.
7. Boivin G. Farlay D. Bala Y. Doublier A. Meunier P. Delmas P. (2009) Influence of remodeling on the mineralization of bone tissue. Osteoporos Int 20: 1023–1026.
8. Boivin G. Farlay D. Khebbab M. Jaurand X. Delmas P. Meunier P. (2010) In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization. Osteoporos Int 21: 667–677.
9. Bonnelye E. Chabadel A. Saltel F. Jurdic P. (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42: 129–138.
10. Breart G. Audran M. Brandi M. Bröll J. Hamdy A. Jakob F. et al. (2009) Good safety and persistence of strontium ranelate in a prospective observational cohort study. Osteoporos Int 20: S94.
11. Breart G. Cooper C. Meyer O. Speirs C. Deltour N. Reginster J. (2010) Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int 21: 1181–1187.
12. Brennan T. Rybchyn M. Green W. Atwa S. Conigrave A. Mason R. (2009) Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 157: 1291–1300.
13. Bruyere O. Collette J. Rizzoli R. Decock C. Ortolani S. Cormier C. et al (2010) Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int 21: 1031–1036.
14. Bruyere O. Roux C. Badurski J. Isaia G. de Vernejoul M. Cannata J. et al (2007) Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 23: 3041–3045.
15. Canalis E. Hott M. Deloffre P. Tsouderos Y. Marie P. (1996) The divalent strontium salt S 12911 enhances bone cell replication and bone formation in vitro. Bone 18: 517–523.
16. Caudrillier A. Hurtel-Lemaire A. Wattel A. Cournarie F. Godin C. Petit L. et al (2010) Strontium ranelate decreases RANKL-induced osteoclastic differentiation in vitro: involvement of the calcium sensing receptor. Mol Pharmacol 78: 569–576.
17. Caverzasio J. (2008) Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. Bone 42: 1131–1136.
18. Chattopadhyay N. Quinn S. Kifor O. Ye C. Brown E. (2007) The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol 74: 438–447.
19. Choudhary S. Halbout P. Alander C. Raisz L. Pilbeam C. (2007) Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: involvement of prostaglandins. J Bone Miner Res 22: 1002–1010.
20. Cooper C. Reginster J. Cortet B. Diaz-Curiel M. Lorenc R. Kanis J. et al (2012) Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 28: 475–491.
21. Dahl S. Allain P. Marie P. Mauras Y. Boivin G. Ammann P. et al (2001) Incorporation and distribution of strontium in bone. Bone 28: 446–453.
22. Doublier A. Farlay D. Khebbab M. Jaurand X. Meunier P. Boivin G. (2011) Distribution of strontium and mineralization in iliac bone biopsies from osteoporotic women treated long-term with strontium ranelate. Eur J Endocrinol 165: 469–476.
23. EMA (2009) Strontium ranelate. Summary of product characteristics. European Medicines Agency. Available at: http://www.emea.europa.eu (accessed 3 March 2013).
24. EMA (2012) Questions and answers on the review of Protelos and Osseor (strontium ranelate). European Medicines Agency. Available at: http://www.emea.europa.eu (accessed 3 March 2013).
25. Farlay D. Boivin G. Panczer G. Lalande A. Meunier P. (2005) Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. J Bone Miner Res 20: 1569–1578.
26. Fournier C. Perrier A. Thomas M. Laroche N. Dumas V. Rattner A. et al (2012) Reduction by strontium of the bone marrow adiposity in mice and repression of the adipogenic commitment of multipotent C3H10T1/2 cells. Bone 50: 499–509.
27. Fromigue O. Hay E. Barbara A. Marie P. (2010) Essential role of nuclear factor of activated T cells (NFAT)-mediated WNT signalling in osteoblast differentiation induced by strontium ranelate. J Biol Chem 285: 25251–25258.
28. Fromigue O. Hay E. Barbara A. Petrel C. Traiffort E. Ruat M. et al (2009) Calcium sensing receptor-dependent and -independent activation of osteoblast replication and survival by strontium ranelate. J Cell Mol Med 13: 2189–2199.
29. Geoffroy V. Chappard D. Marty C. Libouban H. Ostertag A. Lalande A. et al (2011) Strontium ranelate decreases the incidence of new caudal vertebral fractures in a growing mouse model with spontaneous fractures by improving bone microarchitecture. Osteoporos Int 22: 289–297.
30. Goldhahn J. Féron J. Kanis J. Papapoulos S. Reginster J. Rizzoli R. et al (2012) Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 90: 343–353.
31. Hiligsmann M. Bruyère O. Reginster J. (2010 a) Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 21: 157–165.
32. Hiligsmann M. Vanoverberghe M. Neuprez A. Bruyère O. Reginster J. (2010 b) Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 10:359–366.
33. Hurtel-Lemaire A. Mentaverri R. Caudrillier A. Cournarie F. Wattel A. Kamel S. et al (2009) The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J Biol Chem 284: 575–584.
34. Kaufman J. Audran M. Bianchi G. Braga V. Diaz-Curiel M. Francis R. et al. (2013) Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 98: 592–601.
35. Khosla S. Oursler M. Monroe D. (2012) Estrogen and the skeleton. Trends Endocrinol Metab 23: 576–581.
36. Li C. Paris O. Siegel S. Roschger P. Paschalis E. Klaushofer K. et al (2010) Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment. J Bone Miner Res 25: 968–975.
37. Li Y. Feng G. Gao Y. Luo E. Liu X. Hu J. (2009) Strontium ranelate treatment enhances hydroxyapatite-coated titanium screws fixation in osteoporotic rats. J Orthop Res 28: 578–582.
38. Li Y. Li J. Zhu S. Luo E. Feng G. Chen Q. et al (2012) Effects of strontium on proliferation and differentiation of rat bone marrow mesenchymal stem cells. Biochem Biophys Res Commun 418: 725–730.
39. Li Y. Luo E. Feng G. Zhu S. Li J. Hu J. (2010) Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats. Osteoporos Int 21: 1889–1897.
40. Maimoun L. Brennan T. Badoud I. Dubois-Ferriere V. Rizzoli R. Ammann P. (2010) Strontium ranelate improves implant osseointegration. Bone 46: 1436–1441.
41. Marie P. Felsenberg D. Brandi M. (2011) How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int 22: 1659–1667.
42. Marie P. Hott M. Modrowski D. de Pollak C. Guillemain J. Deloffre P. et al (1993) An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8: 607–615.
43. Marquis P. Cialdella P. de La Loge C. (2001) Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. Qual Life Res 10: 555–566.
44. Marquis P. Roux C. de la Loge C. Diaz-Curiel M. Cormier C. Isaia G. et al (2008) Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos Int 19: 503–510.
45. Meunier P. Aaron J. Edouard C. Vignon G. (1971) Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies, Clin Orthop Relat Res 80: 147–154.
46. Meunier P. Roux C. Ortolani S. Diaz-Curiel M. Compston J. Marquis P. et al (2009) Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 20: 1663–1673.
47. Meunier P. Roux C. Seeman E. Ortolani S. Badurski J. Spector T. et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459–468.
48. Musette P. Brandi M. Cacoub P. Kaufman J. Rizzoli R. Reginster J. (2010) Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 21: 723–732.
49. Musette P. Kaufman J. Rizzoli R. Cacoub P. Brandi M. Reginster J. (2011) Cutaneous side effects of antiosteoporosis treatments. Ther Adv Musculoskelet Dis 3: 31–41.
50. Peng S. Liu X. Huang S. Li Z. Pan H. Zhen W. et al (2011 a) The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin. Bone 49: 1290–1298.
51. Peng S. Liu X. Zhou G. Li Z. Luk K. Guo X. et al (2011 b) Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption. J Bone Miner Res 26: 1272–1282.
52. Perrio M. Wilton L. Shakir S. (2008) Analysis of venous thromboembolism in the strontium ranelate prescription-event monitoring (PEM) cohort: interim results. Drug Saf 31: 1.
53. Rabenda V. Reginster J. (2010) Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporos Int 21: 1993–2002.
54. Raisz L. (2005) Pathogenesis of osteoporosis: concepts, conflicts and prospects. J Clin Invest 115: 3318–3325.
55. Recker R. Marin F. Ish-Shalom S. Moricke R. Hawkins F. Kapetanos G. et al (2009) Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 24: 1358–1368.
56. Reginster J. Bruyere O. Collette J. (2012) Strontium ranelate treatment increases osteoprotegerin serum levels in postmenopausal osteoporotic women. Bone 50: 1201–1202; author reply 1203–1204.
57. Reginster J. Bruyère O. Sawicki A. Roces-Varela A. Fardellone P. Roberts A. et al (2009) Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 45: 1059–1064.
58. Reginster J. Felsenberg D. Boonen S. Diez-Perez A. Rizzoli R. Brandi M. et al (2008) Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 58: 1687–1695.
59. Reginster J. Kaufman J. Goemaere S. Devogelaer J. Benhamou C. Felsenberg D. et al (2012) Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 23: 1115–1122.
60. Reginster J. Seeman E. de Vernejoul M. Adami S. Compston J. Phenekos C. et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90: 2816–2822.
61. Ringe J. Dorst A. Farahmand P. (2009) Treatment of glucocorticoid-induced osteoporosis with strontium ranelate: a 2-year observational, controlled study versus risedronate (abstract). Osteoporos Int 20(Suppl. 1): S72.
62. Rizzoli R. Chapurlat R. Laroche J. Krieg M. Thomas T. Frieling I. et al (2012) Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study. Osteoporos Int 23: 305–315.
63. Rizzoli R. Laroche M. Krieg M. Frieling I. Thomas T. Delmas P. et al (2010) Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int 30: 1341–1348.
64. Rizzoli R. Reginster J. Boonen S. Bréart G. Diez-Perez A. Felsenberg D. et al (2011) Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 89: 91–104.
65. Roschger P. Manjubala I. Zoeger N. Meirer F. Simon R. Li C. et al (2010) Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment. J Bone Miner Res 25: 891–900.
66. Roux C. Reginster J. Fechtenbaum J. Kolta S. Sawicki A. Tulassay Z. et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21: 536–542.
67. Seeman E. (2003) Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis. Osteoporos Int 14(Suppl. 3): S2–S8.
68. Seeman E. Boonen S. Borgström F. Vellas B. Aquino J. Semler J. et al (2010) Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone 46: 1038–1042.
69. Seeman E. Devogelaer J. Lorenc R. Spector T. Brixen K. Balogh A. et al (2008) Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 23: 433–438.
70. Seeman E. Vellas B. Benhamou C. Aquino J. Semler J. Kaufman J. et al (2006) Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 21: 1113–1120.
71. Sun P. Cai D. Li Q. Chen H. Deng W. He L. et al (2010) Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats. Calcif Tissue Int 86: 495–501.
72. Takahashi N. Sasaki T. Tsouderos Y. Suda T. (2003) S12911–2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 18: 1082–1087.
73. Zebaze R. Ghasem-Zadeh A. Bohte A. Iuliano-Burns S. Mirams M. Price R. et al (2010) Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 375: 1729–1736.